FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137193055> ?p ?o ?g. }

• W2137193055 endingPage "7833" @default.
• W2137193055 startingPage "7825" @default.
• W2137193055 abstract "Abstract Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Patients and Methods: Thirty-two patients were treated with 92 courses of tasidotin through seven dose levels determined by a modified Fibonacci scheme ranging from 3.9 to 45.7 mg/m2. Pharmacokinetic samples were collected during the first course. Results: Neutropenia was the principal DLT at the 45.7 mg/m2/d dose level. In addition, one patient also experienced grade 3 neutropenia complicated with grade 3 esophageal candidiasis and grade 3 dehydration. Only 1 of 11 patients treated at the MTD, 34.4 mg/m2, experienced dose-limiting neutropenia. Other common, drug-related toxicities included mild to moderate fatigue, anemia, nausea, anorexia, emesis, alopecia, and diarrhea. The best observed antitumor response consisted of stable disease and was noted in 10 patients (31%); the median duration on study for those patients with stable disease was 99.5 days compared with 37.5 days for those patients with progressive disease. Tasidotin plasma concentrations declined biphasically with an effective half-life of ≤55 minutes, and ∼11% was excreted unchanged in the urine. Conclusion: The recommended dose for phase II studies and the MTD when tasidotin is administered on days 1, 3, and 5 every 3 weeks is 34.4 mg/m2. The favorable toxicity profile of tasidotin compared with other antitubulin agents, including other dolastatin analogues, and its novel mechanism of action support further disease-directed evaluation of this agent." @default.
• W2137193055 created "2016-06-24" @default.
• W2137193055 creator A5000776327 @default.
• W2137193055 creator A5001314462 @default.
• W2137193055 creator A5002037553 @default.
• W2137193055 creator A5008468404 @default.
• W2137193055 creator A5008682252 @default.
• W2137193055 creator A5010056933 @default.
• W2137193055 creator A5014325226 @default.
• W2137193055 creator A5017361204 @default.
• W2137193055 creator A5037823936 @default.
• W2137193055 creator A5043169952 @default.
• W2137193055 creator A5045982804 @default.
• W2137193055 creator A5069070518 @default.
• W2137193055 creator A5070720153 @default.
• W2137193055 date "2005-11-01" @default.
• W2137193055 modified "2023-10-17" @default.
• W2137193055 title "Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors" @default.
• W2137193055 cites W1509684747 @default.
• W2137193055 cites W1550111394 @default.
• W2137193055 cites W1589293594 @default.
• W2137193055 cites W1971579914 @default.
• W2137193055 cites W1973771269 @default.
• W2137193055 cites W1983614101 @default.
• W2137193055 cites W1994162165 @default.
• W2137193055 cites W1995751127 @default.
• W2137193055 cites W1999142756 @default.
• W2137193055 cites W2004385676 @default.
• W2137193055 cites W2015545456 @default.
• W2137193055 cites W2017742036 @default.
• W2137193055 cites W2021570592 @default.
• W2137193055 cites W2027515515 @default.
• W2137193055 cites W2039647828 @default.
• W2137193055 cites W2049262877 @default.
• W2137193055 cites W2054755684 @default.
• W2137193055 cites W2081927573 @default.
• W2137193055 cites W2082614632 @default.
• W2137193055 cites W2085519212 @default.
• W2137193055 cites W2120780947 @default.
• W2137193055 cites W2165300068 @default.
• W2137193055 cites W2175618245 @default.
• W2137193055 cites W2181549846 @default.
• W2137193055 cites W2275098532 @default.
• W2137193055 cites W2596717368 @default.
• W2137193055 doi "https://doi.org/10.1158/1078-0432.ccr-05-0058" @default.
• W2137193055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16278405" @default.
• W2137193055 hasPublicationYear "2005" @default.
• W2137193055 type Work @default.
• W2137193055 sameAs 2137193055 @default.
• W2137193055 citedByCount "47" @default.
• W2137193055 countsByYear W21371930552012 @default.
• W2137193055 countsByYear W21371930552013 @default.
• W2137193055 countsByYear W21371930552014 @default.
• W2137193055 countsByYear W21371930552015 @default.
• W2137193055 countsByYear W21371930552016 @default.
• W2137193055 countsByYear W21371930552020 @default.
• W2137193055 countsByYear W21371930552021 @default.
• W2137193055 countsByYear W21371930552022 @default.
• W2137193055 crossrefType "journal-article" @default.
• W2137193055 hasAuthorship W2137193055A5000776327 @default.
• W2137193055 hasAuthorship W2137193055A5001314462 @default.
• W2137193055 hasAuthorship W2137193055A5002037553 @default.
• W2137193055 hasAuthorship W2137193055A5008468404 @default.
• W2137193055 hasAuthorship W2137193055A5008682252 @default.
• W2137193055 hasAuthorship W2137193055A5010056933 @default.
• W2137193055 hasAuthorship W2137193055A5014325226 @default.
• W2137193055 hasAuthorship W2137193055A5017361204 @default.
• W2137193055 hasAuthorship W2137193055A5037823936 @default.
• W2137193055 hasAuthorship W2137193055A5043169952 @default.
• W2137193055 hasAuthorship W2137193055A5045982804 @default.
• W2137193055 hasAuthorship W2137193055A5069070518 @default.
• W2137193055 hasAuthorship W2137193055A5070720153 @default.
• W2137193055 hasConcept C112705442 @default.
• W2137193055 hasConcept C126322002 @default.
• W2137193055 hasConcept C2777063308 @default.
• W2137193055 hasConcept C2778248108 @default.
• W2137193055 hasConcept C2778654693 @default.
• W2137193055 hasConcept C2779802037 @default.
• W2137193055 hasConcept C2780580376 @default.
• W2137193055 hasConcept C2780852908 @default.
• W2137193055 hasConcept C29730261 @default.
• W2137193055 hasConcept C71924100 @default.
• W2137193055 hasConcept C90924648 @default.
• W2137193055 hasConcept C98274493 @default.
• W2137193055 hasConceptScore W2137193055C112705442 @default.
• W2137193055 hasConceptScore W2137193055C126322002 @default.
• W2137193055 hasConceptScore W2137193055C2777063308 @default.
• W2137193055 hasConceptScore W2137193055C2778248108 @default.
• W2137193055 hasConceptScore W2137193055C2778654693 @default.
• W2137193055 hasConceptScore W2137193055C2779802037 @default.
• W2137193055 hasConceptScore W2137193055C2780580376 @default.
• W2137193055 hasConceptScore W2137193055C2780852908 @default.
• W2137193055 hasConceptScore W2137193055C29730261 @default.
• W2137193055 hasConceptScore W2137193055C71924100 @default.
• W2137193055 hasConceptScore W2137193055C90924648 @default.
• W2137193055 hasConceptScore W2137193055C98274493 @default.
• W2137193055 hasIssue "21" @default.
• W2137193055 hasLocation W21371930551 @default.

• next